Chung-Han Lee, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, reports recent findings from a study using pembrolizumab and lenvatinib as a second-line treatment for clear cell renal cell carcinoma (ccRCC). Dr. Lee states that patients in the trial exhibited a 55% objective response rate...

Suresh Ramalingam, MD, FASCO, deputy director, Winship Cancer Institute of Emory University, addresses autoimmune toxicities associated with combination immune therapies as in the CheckMate-227 trial for non-small cell lung cancer (NSCLC). Dr. Ramalingam asserts that most of these salient toxicities occur...

Joshua K. Sabari, MD, assistant professor in the Department of Medicine at NYU Langone Health’s Perlmutter Cancer Center, addresses the need for additional predictive biomarkers for non-small cell lung cancer (NSCLC) patients with no known driver mutation. Dr. Sabari says, to date, PD-L1 is the only...